Clinical Trial Update: Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC [Phase 2]

View source ↗

Summary

A Phase 2 study of Basimglurant (NOE-101) in children, adolescents, and young adults with tuberous sclerosis complex has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberous Sclerosis Complex

Drugs mentioned

• Basimglurant (NOE-101) (basimglurant)

Snippet

Sponsor: Noema Pharma AG | Conditions: Tuberous Sclerosis Complex | Phase 2 | Status: COMPLETED